Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2005 3
2006 3
2007 1
2008 3
2009 1
2010 1
2011 1
2013 2
2014 4
2015 1
2016 1
2017 1
2020 2
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.
Zeitlinger M, Bauer M, Reindl-Schwaighofer R, Stoekenbroek RM, Lambert G, Berger-Sieczkowski E, Lagler H, Oesterreicher Z, Wulkersdorfer B, Lührs P, Galabova G, Schwenke C, Mader RM, Medori R, Landlinger C, Kutzelnigg A, Staffler G. Zeitlinger M, et al. Among authors: kutzelnigg a. Eur J Clin Pharmacol. 2021 Oct;77(10):1473-1484. doi: 10.1007/s00228-021-03149-2. Epub 2021 May 10. Eur J Clin Pharmacol. 2021. PMID: 33969434 Free PMC article. Clinical Trial.
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.
Poewe W, Volc D, Seppi K, Medori R, Lührs P, Kutzelnigg A, Djamshidian A, Thun-Hohenstein C, Meissner WG, Rascol O, Schneeberger A, Staffler G; AFF011 investigators; AFF011 study investigators:, Poewe W, Seppi K, Djamshidian A, deMarzi R, Heim B, Mangesius S, Stolz R, Wachowicz K, Volc D, Thun-Hohenstein C, Riha C, Schneeberger A, Bürger V, Galabova G. Poewe W, et al. Among authors: kutzelnigg a. J Parkinsons Dis. 2021;11(3):1079-1089. doi: 10.3233/JPD-212594. J Parkinsons Dis. 2021. PMID: 34092654 Free PMC article. Clinical Trial.
A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.
Meissner WG, Traon AP, Foubert-Samier A, Galabova G, Galitzky M, Kutzelnigg A, Laurens B, Lührs P, Medori R, Péran P, Sabatini U, Vergnet S, Volc D, Poewe W, Schneeberger A, Staffler G, Rascol O; AFF009 Study Investigators. Meissner WG, et al. Among authors: kutzelnigg a. Mov Disord. 2020 Nov;35(11):1957-1965. doi: 10.1002/mds.28218. Epub 2020 Sep 3. Mov Disord. 2020. PMID: 32882100 Free PMC article. Clinical Trial.
[Significance of Ginkgo biloba extract in dementia].
Kasper S, Winkler D, Kutzelnigg A. Kasper S, et al. Among authors: kutzelnigg a. Pharm Unserer Zeit. 2009;38(5):424-30. doi: 10.1002/pauz.200900330. Pharm Unserer Zeit. 2009. PMID: 19711318 Review. German. No abstract available.
Cortical lesions and brain atrophy in MS.
Kutzelnigg A, Lassmann H. Kutzelnigg A, et al. J Neurol Sci. 2005 Jun 15;233(1-2):55-9. doi: 10.1016/j.jns.2005.03.027. J Neurol Sci. 2005. PMID: 15893328 Review.
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
Volc D, Poewe W, Kutzelnigg A, Lührs P, Thun-Hohenstein C, Schneeberger A, Galabova G, Majbour N, Vaikath N, El-Agnaf O, Winter D, Mihailovska E, Mairhofer A, Schwenke C, Staffler G, Medori R. Volc D, et al. Among authors: kutzelnigg a. Lancet Neurol. 2020 Jul;19(7):591-600. doi: 10.1016/S1474-4422(20)30136-8. Lancet Neurol. 2020. PMID: 32562684 Clinical Trial.
The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography.
Vanicek T, Spies M, Rami-Mark C, Savli M, Höflich A, Kranz GS, Hahn A, Kutzelnigg A, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Volkow ND, Kasper S, Lanzenberger R. Vanicek T, et al. Among authors: kutzelnigg a. JAMA Psychiatry. 2014 Dec 1;71(12):1340-1349. doi: 10.1001/jamapsychiatry.2014.1226. JAMA Psychiatry. 2014. PMID: 25338091 Free PMC article.
Multiple sclerosis and Alzheimer's disease.
Dal Bianco A, Bradl M, Frischer J, Kutzelnigg A, Jellinger K, Lassmann H. Dal Bianco A, et al. Among authors: kutzelnigg a. Ann Neurol. 2008 Feb;63(2):174-83. doi: 10.1002/ana.21240. Ann Neurol. 2008. PMID: 17924575
27 results